Heidelberg Pharma AG (HPHA) Stock Statistics & Valuation Metrics

Heidelberg Pharma AG has a market cap or net worth of €150.52M. The enterprise value is ―.

Heidelberg Pharma AG has 46,601,097 shares outstanding. The number of shares has decreased by -2.65% in one year.

Heidelberg Pharma AG’s return on equity (ROE) is -0.63 and return on invested capital (ROIC) is -46.48%.

The current PE Ratio of Heidelberg Pharma AG is -5.77. Heidelberg Pharma AG’s PEG ratio is 0.93.

In the last 12 months, Heidelberg Pharma AG had revenue of 6.85M and earned -19.38M in profits. Earnings per share was -0.42.

In the last 12 months, operating cash flow was -27.42M and capital expenditures -517.99K, giving a free cash flow of -27.94M billion.

Heidelberg Pharma AG pays an annual dividend of ―, resulting in a dividend yield of ―

Heidelberg Pharma AG upcoming earnings date is Jul 10, 2025, TBA Not Confirmed.

Heidelberg Pharma AG as a current ratio of 5.95, with Debt / Equity ratio of 0.61%

In the past 12 months, Heidelberg Pharma AG has paid 0.00 in taxes.

Heidelberg Pharma AG EV to EBITDA ratio is -5.68, with an EV/FCF ratio of -3.48.

Heidelberg Pharma AG has €20.68M in cash and marketable securities with €151.89K in debt, giving a net cash position of -€20.53M billion.

Gross margin is 64.14%, with operating margin of -358.55%, and net profit margin of -282.98%.

The average price target for Heidelberg Pharma AG is ―, which is 11.43% higher than the current price. The consensus rating is ―